<DOC>
	<DOCNO>NCT00970580</DOCNO>
	<brief_summary>The purpose study determine whether BIIB022 , Paclitaxel Carboplatin effective treatment Treatment-Naive , Stage IIIB/IV Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>A Study BIIB022 Combination With Paclitaxel Carboplatin Subjects With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Antimitotic Agents</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age &gt; /= 18 year old Treatmentnaive Stage IIIB/IV NonSmall Cell Lung Cancer ECOG Performance Status 0 1 History another primary cancer within 3 year Any prior concurrent investigational standard therapy treatment NSCLC Prior antiIGF1R therapy Unstable diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>BIIB022</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Taxol</keyword>
	<keyword>Stage IIIB</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Anti IGF1R</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Open Label</keyword>
	<keyword>IGF1R</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Cytotoxic</keyword>
	<keyword>Mitotic Inhibitor</keyword>
	<keyword>Taxane</keyword>
	<keyword>Alkylating agent</keyword>
</DOC>